drugset / Trial / NCT05229562

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

NCT05229562

Phase 1 Completed 84 enrolled Biogen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will be looking at an investigational drug, BIIB122, in healthy adult Japanese, Chinese, and Caucasian participants. The main goal of the study is to compare the drug level achieved in the body, between the different ethnic groups, after single and multiple doses of BIIB122. Researchers also want to see if single and multiple doses of BIIB122 are safe and if healthy participants can tolerate given doses of BIIB122.

Timeline

Start
2022-02-17
Primary completion
2022-09-07
Completion
2022-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB122 Small molecule Oral

Indications

No indication recorded.